Diethylstilbestrol

Hormone Therapy
DB00255
Approved Indication

Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.

9 Targets
0 Resistance Mutations
5 References
3ERD Structure Loaded
3D Structure PDB: 3ERD
Switch structure: RCSB ↗
Mechanism of Action

Estrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Details
DrugBank ID DB00255 ↗
Approval Date —
Molecular Weight 268.3502 g/mol
Drug Class Hormone Therapy
ATC Codes L02AA01, G03CC05, L02AA04, G03CB02
Synonyms DES, Diethylstilbestrol, Diethylstilbestrolum
SMILES
CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ADMET Profile
Computing properties…